EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma

June 04, 2013

Surgical resection is considered a potentially curative treatment for pancreatic adenocarcinoma, however, the five year survival rate of patients receiving this treatment is less than 20 percent. Adjuvant treatment, therefore, is used to prevent recurrence and improve survival for these patients.

EORTC trial 40084-22084 has two primary objectives: to determine if adding erlotinib to gemcitabine adjuvant chemotherapy will improve survival as compared to gemcitabine alone following resection of head of pancreas adenocarcinoma, then, following adjuvant chemotherapy, determine if concurrent fluoropyrimidine and radiotherapy improves survival for patients who have no evidence of progressive disease.

Gemcitabine is a cytotoxic drug which has improved survival in adjuvant chemotherapy for pancreatic cancer. Erlotinib is a tyrosine kinase inhibitor and a strong, reversible, inhibitor of the epidermal growth factor receptor (EGFR). As a targeted agent blocking EGFR signaling, erlotinib has shown a significant albeit modest effect on survival in patients with metastatic pancreatic cancer and should be evaluated in earlier-stage disease where the magnitude of observed benefit may be increased.

Chemoradiation might improve survival for patients with pancreatic cancer, but there is no definitive evidence to establish the inclusion of chemoradiation in their treatment plan. It is thought that adjuvant chemoradiation, i.e. radiation plus concurrent fluoropyrimidine, will increase survival for patients with resected head of pancreas adenocarcinoma who remain disease free after adjuvant chemotherapy with gemcitabine or gemcitabine and erlotinib.

Dr. Jean-Luc Van Laethem of the Hôpitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels and coordinator of this study says, "this protocol is a very good opportunity to definitively answer the question of adding radiation therapy in the adjuvant setting of pancreatic cancer, and to build an ambitious translational research program based on large scale tissue biobanking."

EORTC trial 40084 - 22084 plans to accrue 950 patients overall and 300 patients at 23 EORTC sites located in seven countries: Belgium, France, the United Kingdom, Germany, Italy, Spain, and Switzerland. Pancreatic adenocarcinoma is a relatively rare disease, and such a study is only possible in an academic intergroup setting.
The trial is sponsored by the sponsored by the NCI in the US and by the EORTC in Europe, led by the Radiation Therapy Oncology Group in collaboration with the EORTC Gastrointestinal Tract Cancer Group, the EORTC Radiation Oncology Group, and the Southwest Oncology Group, and is an academic investigator driven clinical trial without financial support from the industry. Erlotinib is supplied by Roche.

For more information concerning EORTC trial 40084 - 22084 please contact:http://www.eortc.org/contact

European Organisation for Research and Treatment of Cancer

Related Pancreatic Cancer Articles from Brightsurf:

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Nerves keep pancreatic cancer cells from starving
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients.

Pancreatic cancer: Subtypes with different aggressiveness discovered
To date, no targeted personalized therapies for pancreatic cancer exist.

Bringing the 'sticky' back to pancreatic cancer
A multidisciplinary team of researchers at Japan's Tohoku University has found that a gene regulator, called BACH1, facilitates the spread of pancreatic cancer to other parts of the body.

Does lung damage speed pancreatic cancer?
High levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.

Scientists have identified the presence of cancer-suppressing cells in pancreatic cancer
Researchers have identified cells containing a protein called Meflin that has a role in restraining the progression of pancreatic cancer.

Pancreatic cancer discovery reveals how the aggressive cancer fuels its growth
A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work -- and for whom they will fail.

Overcoming resistance in pancreatic cancer
In pancreatic cancer cells' struggle to survive, the cells choose alternative routes when their main pathways are blocked by drugs.

Exposing how pancreatic cancer does its dirty work
Pancreatic cancer is a puzzle -- tumors slough off cells into the bloodstream early in the disease, but the tumors themselves have almost no blood vessels in them.

Targeting cell division in pancreatic cancer
Study provides new evidence of synergistic effects of drugs that inhibit cell division and support for further clinical trials.

Read More: Pancreatic Cancer News and Pancreatic Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.